Treatment with donepezil in Alzheimer patients with and without cerebrovascular disease

Journal of the Neurological Sciences

Volumn 203-204, Issue , 2002, Pages 137-139

  Frolich L ^a   Klinger, T ^b   Berger, F M ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Klinikum St Georg   (Germany)

^c Eisai GmbH   (Germany)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Observational clinical study

Indexed keywords

DONEPEZIL; GINKGO BILOBA EXTRACT; MEMANTINE; NOOTROPIC AGENT; PIRACETAM;

ADULT; AGED; AGGRESSIVENESS; AGITATION; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; FEMALE; GERMANY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; FEMALE; GERMANY; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; QUALITY OF LIFE;

EID: 0037111459     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00275-7     Document Type: Conference Paper

References (11)

1. Burns A., Rossor M., Hecker J.et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord. 10:1999;237-244.
2. Rogers S.L., Farlow M.R., Doody R.S.et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
3. Rogers S.L., Doody R.S., Mohs R.C.et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. 158:1998;1021-1031.
4. Rogers S.L., Friedhoff L.T. the Donepezil Study Group The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind trial. Dementia. 7:1996;293-303.
5. Mohs R.C., Doody R.S., Morris J.C.et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 57:2001;481-488.
6. Winblad B., Engedal K., Soininen H.et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 57:2001;489-495.
7. Rogers S.L., Doody R.S., Pratt R.D.et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur. Neurol. 10:2000;195-203.
8. Doody R.S., Geldmacher D.S., Gordon B.et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch. Neurol. 58:2001;427-433.
9. Berger F.M., Goebel C., Sramko C.A. Donepezil in the treatment of Alzheimer's disease: results from a post-marketing surveillance study in Germany. J. Neurol. 247(Suppl. 3):2000;104. [P403].
10. Demers L., Oremus M., Perrault A.et al. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales. J. Geriatr. Psychiatry Neurol. 13:2000;170-180.
11. Schneider L.S., Olin J.T., Lyness S.A., Chui H.C. Eligibility of Alzheimer's disease clinic patients for clinical trials. J. Am. Geriatr. Soc. 45:1997;923-928.